

Table S1. Number of detected organisms, resistance phenotypes (per conventional methods) and resistance genes (per BCID2 Panel) in patients of the pre-BCID2 ($n = 87$) and BCID2 ($n = 85$) implementation periods with at least one detected pathogen.

Organism	Pre-BCID2 organisms ($n = 91$)		BCID2-phase organisms ($n = 98$)		
	N	Resistance phenotype	N	Resistance phenotype	Resistance genes (BCID2 panel)
<i>Klebsiella pneumoniae</i>	19	ESBL ($n = 3$); AmpC ($n = 1$); CPE ($n = 4$); CRE ($n = 1$)	12	ESBL ($n = 1$); CPE ($n = 1$)	CTX-M ($n = 4$); OXA-48-like ($n = 1$); CTX-M + NDM ($n = 1$); CTX-M + OXA-48-like ($n = 1$)
<i>Escherichia coli</i>	14		13	ESBL ($n = 1$); AmpC ($n = 1$)	CTX-M ($n = 7$); <i>mcr-1</i> ($n = 1$); NDM ($n = 1$)
<i>Staphylococcus epidermidis</i>	10		10		<i>mecA/C</i> ($n = 10$)
<i>Candida auris</i>	0		13		
<i>Candida tropicalis</i>	2		6		
<i>Staphylococcus aureus</i>	6	MRSA ($n = 2$)	1		
<i>Candida parapsilosis</i>	4		5		
<i>Staphylococcus capitis</i>	5		4		
<i>Staphylococcus haemolyticus</i>	4		2		
<i>Staphylococcus hominis</i>	4		2		
<i>Acinetobacter baumannii</i> complex	1		4		
<i>Enterococcus faecalis</i>	2		2		
<i>Enterobacter cloacae</i> complex	2		2		
<i>Serratia marcescens</i>	1		2		
<i>Enterococcus faecium</i>	1		2		
<i>Streptococcus pneumoniae</i>	1		2		
<i>Stenotrophomonas maltophilia</i>	2		0		
<i>Elizabethkingia meningoseptica</i>	0		2		
<i>Klebsiella aerogenes</i>	0		2		OXA-48-like ($n = 1$)
<i>Streptococcus viridans</i>	0		2		
<i>Corynebacterium</i> spp.	1		1		
<i>Candida albicans</i>	1		1		
<i>Candida krusei</i>	1		1		
<i>Pseudomonas aeruginosa</i>	0		1		
<i>Candida glabrata</i>	1		0		
<i>Enterococcus gallinarum</i>	1		0		
Others	8 ¹		6 ²		

¹ One each of the following: *Burkholderia cepacia*, *Klebsiella Ozaenae*, *Lactobacillus casei*, *Proteus mirabilis*, *Rothia mucilaginosa*, *Salmonella* species, *Weissella confusa*, *Leuconostoc pseudomesenteroides*; ² One each of the following: *Staphylococcus* spp., *Bacteroides fragilis*, *Enterococcus Avium* Group D, *Kytococcus* spp., *Streptococcus oralis*, *Aeromonas sobria*. Abbreviations: AmpC, class C beta-lactamase; CPE, carbapenemase-producing enterobacteriaceae; CRE, Carbapenem-resistant enterobacteriaceae; ESBL, positive for extended spectrum beta-lactamase; MRSA, methicillin-resistant *Staphylococcus aureus*.

Table S2. Resistance and susceptibility to antimicrobial treatment in the pre-BCID2 implementation phase.

Antimicrobial medication	Resistant	Susceptible	Total number of isolates tested	% tested isolates susceptible to medication
AMIKACIN	4	38	42	90.5
AMOXICILLIN/CLAVUL.	15	28	43	65.1
AMPHOTERICIN B	0	8	8	100.0
AMPICILLIN	31	12	43	27.9
CASPOFUNGIN	2	6	8	75.0
CEFACLO	0	5	5	100.0
CEFAZOLIN	0	5	5	100.0
CEFEPIME	17	34	51	66.7
CEFIXIME	0	5	5	100.0
CEFOTAXIME	21	22	43	51.2
CEFTAZIDIME	20	29	49	59.2
CEFTAZIDIME AVIBACTAM	4	0	4	0.0
CEFTOLOZANE TAZOBACTAM	7	22	29	75.9
CEFTRIAZONE	16	28	44	63.6
CEFUROXIME	13	11	24	45.8
CIPROFLOXACIN	24	32	56	57.1
CLINDAMYCIN	9	12	21	57.1
COLISTIN	0	4	4	100.0
ERTAPENEM	7	34	41	82.9
FLUCONAZOLE	4	2	6	33.3
FLUCYTOSINE	1	7	8	87.5
FOSFOMYCIN	7	30	37	81.1
GENTAMICIN	12	52	64	81.3
IMIPENEM	8	34	42	81.0
LEVOFLOXACIN	11	14	25	56.0
LINEZOLID	0	27	27	100.0
MEROPENEM	7	39	46	84.8
MICAFUNGIN	1	7	8	87.5
MOXIFLOXACIN	6	6	12	50.0
NORFLOXACIN	13	23	36	63.9
PIPERACILLIN/TAZOBACTAM	11	36	47	76.6
RIFAMPICIN	2	15	17	88.2
TEICOPLANIN	0	15	15	100.0
TIGECYCLINE	0	20	20	100.0
TRIMETHOPRIM (TMP)	18	44	62	71.0
TOBRAMYCIN	6	18	24	75.0
VANCOMYCIN	4	24	28	85.7
VORICONAZOLE	1	8	9	88.9

Table S3. Resistance and susceptibility to antimicrobial treatment in the BCID2 implementation phase.

Antimicrobial medication	Resistant	Susceptible	Total number of isolates tested	% tested isolates susceptible to medication
AMIKACIN	3	28	31	90.3
AMOXICILLIN/CLAVUL.	17	13	30	43.3
AMPHOTERICIN B	0	12	12	100.0
AMPICILLIN	26	6	32	18.8
CASPOFUNGIN	0	9	9	100.0
CEFACLOR	4	4	8	50.0
CEFAZOLIN	4	1	5	20.0
CEFEPIME	16	19	35	54.3
CEFIXIME	4	3	7	42.9
CEFOTAXIME	19	12	31	38.7
CEFTAZIDIME	19	14	33	42.4
CEFTAZIDIME AVIBACTAM	0	8	8	100.0
CEFTOLOZANE TAZOBACTAM	3	10	13	76.9
CEFTRIAZONE	13	17	30	56.7
CEFUROXIME	18	7	25	28.0
CIPROFLOXACIN	16	21	37	56.8
CLINDAMYCIN	10	7	17	41.2
COLISTIN	0	5	5	100.0
ERTAPENEM	6	26	32	81.3
FLUCONAZOLE	2	8	10	80.0
FLUCYTOSINE	1	11	12	91.7
FOSFOMYCIN	6	20	26	76.9
GENTAMICIN	10	37	47	78.7
IMIPENEM	7	25	32	78.1
LEVOFLOXACIN	12	16	28	57.1
LINEZOLID	1	23	24	95.8
MEROPENEM	7	26	33	78.8
MICAFUNGIN	0	9	9	100.0
MOXIFLOXACIN	5	6	11	54.5
NORFLOXACIN	5	11	16	68.8
PIPERACILLIN/TAZOBACTAM	15	18	33	54.5
RIFAMPICIN	0	16	16	100.0
TEICOPLANIN	4	14	18	77.8
TIGECYCLINE	0	23	23	100.0
TRIMETHOPRIM (TMP)	12	39	51	76.5
TOBRAMYCIN	7	25	32	78.1
VANCOMYCIN	1	25	26	96.2
VORICONAZOLE	0	12	12	100.0

Table S4. Discordant pathogens detected by conventional culture *vs.* the BCID2 Panel among patients in the BCID2 implementation period ($n = 24$ discordant pathogens in $n = 18$ patients).

Patient	Organism identified by conventional culture	Organism identified by BCID2
1	<i>Staphylococcus hominis</i> ¹	<i>Staphylococcus epidermidis</i>
2	<i>Staphylococcus haemolyticus</i> ¹	<i>Staphylococcus epidermidis</i>
3	No detection	<i>Candida auris</i>
3	No detection	<i>Staphylococcus epidermidis</i>
4	No detection	<i>Acinetobacter baumannii</i> complex
5	No detection	<i>Klebsiella pneumoniae</i>
6	No detection	<i>Streptococcus pneumoniae</i>
7	<i>Corynebacterium</i> spp. ²	No detection
8	<i>Pseudomonas aeruginosa</i>	No detection
9	<i>Kytococcus</i> spp. ²	No detection
10	<i>Staphylococcus haemolyticus</i> ¹	No detection
11	<i>Aeromonas sobria</i> ²	No detection
12	<i>Enterococcus Avium</i> Group D ²	No detection
13	<i>Candida krusei</i>	No detection
14	<i>Candida tropicalis</i>	No detection
15	<i>Serratia marcescens</i>	No detection
16	<i>Elizabethkingia meningoseptica</i> ²	<i>Escherichia coli</i>
17	<i>Elizabethkingia meningoseptica</i> ²	<i>Candida auris</i>
18	<i>Streptococcus viridans</i> ¹	<i>Staphylococcus</i> spp.

¹ Species not included in the BCID2 panel (but respective genus – *Staphylococcus* spp. and *Streptococcus* spp. – are on panel); ² Off-panel microorganisms (not included in the BCID2 panel).